The pharmaceutical company reported robust growth in domestic formulations and insulin franchise performance, while maintaining a strong EBITDA margin of 37 per cent
The pharmaceutical company reported robust growth in domestic formulations and insulin franchise performance, while maintaining a strong EBITDA margin of 37 per cent by Soban News (international And National News)
